Freeline Therapeutics (FRLN) to Release Earnings on Wednesday

Freeline Therapeutics (NASDAQ:FRLN) will be announcing its earnings results on Wednesday, November 22nd.

Freeline Therapeutics Trading Up 14.7 %

Shares of NASDAQ:FRLN opened at $5.76 on Tuesday. The firm has a 50 day simple moving average of $4.43 and a 200-day simple moving average of $3.77. The company has a market capitalization of $25.00 million, a PE ratio of -0.69 and a beta of 0.39. Freeline Therapeutics has a twelve month low of $2.11 and a twelve month high of $10.20.

Institutional Trading of Freeline Therapeutics

Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in shares of Freeline Therapeutics in the first quarter valued at about $30,000. Northern Trust Corp purchased a new position in shares of Freeline Therapeutics in the 2nd quarter valued at approximately $40,000. Federated Hermes Inc. raised its stake in shares of Freeline Therapeutics by 50.0% during the first quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after purchasing an additional 20,000 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Freeline Therapeutics by 17.4% during the first quarter. Renaissance Technologies LLC now owns 230,600 shares of the company’s stock worth $105,000 after purchasing an additional 34,210 shares during the last quarter. Finally, UBS Group AG acquired a new stake in shares of Freeline Therapeutics during the first quarter worth $565,000. Institutional investors and hedge funds own 46.26% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on FRLN. Wedbush downgraded shares of Freeline Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $8.00 to $5.00 in a research note on Wednesday, October 18th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Freeline Therapeutics in a report on Thursday, August 17th.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease.